نتایج جستجو برای: nvp

تعداد نتایج: 1232  

2012
Shane Zaidi Martin McLaughlin Shreerang A. Bhide Suzanne A. Eccles Paul Workman Christopher M. Nutting Robert A. Huddart Kevin J. Harrington

BACKGROUND Heat shock protein 90 (HSP90) is a molecular chaperone responsible for the conformational maintenance of a number of client proteins that play key roles in cell cycle arrest, DNA damage repair and apoptosis following radiation. HSP90 inhibitors exhibit antitumor activity by modulating the stabilisation and activation of HSP90 client proteins. We sought to evaluate NVP-AUY922, the mos...

2002
Catherine Jane MacKinnon

OCTOBER 2002 Abstract Objectives: To review the evidence-based management of nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum. Evidence: MEDLINE and Cochrane database searches were performed using the medical subject headings (MeSH) of treatment, nausea, vomiting, pregnancy, and hyperemesis gravidarum. The quality of evidence reported in these guidelines has been described usin...

Journal: :Molecular cancer therapeutics 2012
Sauveur-Michel Maira Sabina Pecchi Alan Huang Matthew Burger Mark Knapp Dario Sterker Christian Schnell Daniel Guthy Tobi Nagel Marion Wiesmann Saskia Brachmann Christine Fritsch Marion Dorsch Patrick Chène Kevin Shoemaker Alain De Pover Daniel Menezes Georg Martiny-Baron Doriano Fabbro Christopher J Wilson Robert Schlegel Francesco Hofmann Carlos García-Echeverría William R Sellers Charles F Voliva

Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different chemical classes with a different selectivity profile. The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacologic evaluation of selected compounds during the medici...

2012
Sauveur-Michel Maira Sabina Pecchi Alan Huang Matthew Burger Mark Knapp Dario Sterker Christian Schnell Daniel Guthy Tobi Nagel Marion Wiesmann Saskia Brachmann Christine Fritsch Doriano Fabbro Christopher J. Wilson Robert Schlegel Francesco Hofmann Charles F. Voliva

Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors fromdifferent chemical classeswith a different selectivity profile. The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacologic evaluation of selected compounds during the medicina...

Journal: :The Journal of pharmacology and experimental therapeutics 2002
Alexandre Trifilieff Daniel Wyss Christoph Walker Lazzaro Mazzoni Rene Hersperger

We investigated the pharmacology of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, by using 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171) as a representative compound and compared its potency with the most advanced PDE4 inhibitor, undergoing clinical trials, Ariflo [cis-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Anna V Galkin Jonathan S Melnick Sungjoon Kim Tami L Hood Nanxin Li Lintong Li Gang Xia Ruo Steensma Greg Chopiuk Jiqing Jiang Yongqin Wan Peter Ding Yi Liu Fangxian Sun Peter G Schultz Nathanael S Gray Markus Warmuth

Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large-cell lymphomas (ALCLs). We have identified a highly potent and selective small-molecule ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) values between 2 and 10 n...

2015
Sébastien Jeay Swann Gaulis Stéphane Ferretti Hans Bitter Moriko Ito Thérèse Valat Masato Murakami Stephan Ruetz Daniel A Guthy Caroline Rynn Michael R Jensen Marion Wiesmann Joerg Kallen Pascal Furet François Gessier Philipp Holzer Keiichi Masuya Jens Würthner Ensar Halilovic Francesco Hofmann William R Sellers Diana Graus Porta Joaquin M Espinosa

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a ...

Journal: :Managed care 2008
James P Reichmann Michael S Kirkbride

Nausea and vomiting of pregnancy (NVP) can range from morning sickness to moderate NVP to hyperemesis gravidarum (HG). If it is left unmanaged, health plans may pay for expensive unproven outpatient therapies that are not necessary for treatment of simple morning sickness or moderate NVP. Meanwhile, patients with serious hyperemesis gravidarum whose treatment is delayed may suffer needlessly, e...

2015
Doris Mutabazi Mwesigire Albert W. Wu Faith Martin Achilles Katamba Janet Seeley

BACKGROUND The goal of antiretroviral therapy (ART) is to suppress viral replication, reduce morbidity and mortality, and improve quality of life (QoL). For resource-limited settings, the World Health Organization recommends a first-line regimen of two-nucleoside reverse-transcriptase inhibitors and one non-nucleoside transcriptase inhibitor (nevirapine (NVP) or efavirenz (EFV)). There are few ...

Journal: :The Journal of infectious diseases 2001
S H Eshleman G Becker-Pergola M Deseyve L A Guay M Mracna T Fleming S Cunningham P Musoke F Mmiro J B Jackson

In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (Nvp(R)) in women enrolled in HIV...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید